# US 2025/0082592 A1 · PHARMACEUTICAL COMPOSITION FOR PREVENTION, ALLEVIATION OR TREATMENT OF SARCOPENIA, CONTAINING ROR-alpha ACTIVATOR JC1-40

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082592 A1
- Document ID: US20250082592A1
- Status: Published application
- Kind: A1
- Application number: 18/511,106
- Filed: 2022-05-13
- Published: 2025-03-13
- Earliest claimed: 2021-05-17
- Assignees: Seoul National University R&Db Foundation
- Applicants: Seoul National University R & Db Foundation
- Inventors: Mi-Ock LEE; Hyeung-Geun PARK; Hyeon-Ji KIM
- Web page: https://patentgrep.com/patent/US20250082592A1

## CPC

- A61K 31/17: having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine (isoureas, isothioureas A61K31/155; sulfonylureas A61K31/64)
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a pharmaceutical composition for the prevention, alleviation or treatment of muscular dystrophy, containing a RORα activator JC1-40. A composition according to the present invention increases mitochondrial membrane potential, increases the number of mitochondria, and increases the expression or activity of mitochondria-related genes or proteins to thus increase biosynthesis of mitochondria, and is thus expected to be effective in the prevention, alleviation and treatment of muscular dystrophy.

## Claims

### Claim 1

A method of preventing, improving, or treating sarcopenia, comprising the step of administering a composition comprising JC1-40 or a pharmaceutically acceptable salt thereof as an active ingredient to a subject in need thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the JC1-40 is an activator of RORα protein.

### Claim 3 (depends on 1)

The method of claim 1, wherein the JC1-40 is comprised at a concentration of 1 to 100 M relative to the total composition.

### Claim 4 (depends on 1)

The method of claim 1, wherein the JC1-40 satisfies at least one of the following:
a) increasing mitochondrial membrane potential;
b) increasing mitochondrial quantity; and
c) increasing mitochondrial biosynthesis.

### Claim 5 (depends on 1)

The method of claim 1, wherein the JC1-40 increases the expression or activity of a gene or protein selected from the group consisting of SDHA, COX5A, MCAD, PGC-1α, NRF1, NRF2α, and TFAM.

### Claim 6 (depends on 5)

The method of claim 5, wherein the expression of the TFAM gene or protein is dependent on RORα.

### Claim 7 (depends on 1)

The method of claim 1, wherein the sarcopenia is obese sarcopenia or senile sarcopenia.

### Claim 8

(canceled)

### Claim 9

A method of improving muscular function, comprising the step of administering a cosmetic composition comprising JC1-40 or a cosmetically acceptable salt thereof as an active ingredient to a subject in need thereof.

### Claim 10

A method of increasing mitochondrial biosynthesis, comprising the step of administering a composition comprising JC1-40 or a pharmaceutically acceptable salt thereof as an active ingredient to a subject in need thereof.

### Claim at position 11

11-19. (canceled)
